Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology has safely dosed the first Hong Kong patient and third overall in its CPACS Phase 1 trial of RC220 in advanced solid tumours, completing recruitment of the initial dose cohort. No phlebitis, dose-limiting toxicities, or other adverse events have been reported at the 40 mg/m2 dose, enabling Safety Review Committee assessment and potential escalation to 80 mg/m2 under an updated trial protocol.
The open-label, multi-site study across Australia, Hong Kong and South Korea is using an ascending-dose, Bayesian design to establish the safety, tolerability, pharmacokinetics and maximum tolerated combined dose of RC220 with doxorubicin, while also tracking cardioprotective biomarkers. Following interim analysis, an additional cohort will assess the optimal combination dose in more patients for further safety and early cardioprotective and anticancer efficacy signals, with Racura planning regular trial progress updates that could influence its positioning in cardio-oncology and solid tumour treatment.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology is an ASX-listed, Phase 3-stage clinical biopharmaceutical company focused on cancer care. Its lead asset, (E,E)-bisantrene, is a small-molecule anticancer agent targeting G4-DNA and RNA to inhibit the cancer growth regulator MYC, and is being advanced as proprietary formulation RC220 across multiple oncology indications including AML, EGFRm NSCLC and solid tumours. The company holds long-term patent protection over (E,E)-bisantrene and collaborates with global academic and clinical partners while actively exploring strategic deals to broaden access to RC220.
Average Trading Volume: 163,333
Technical Sentiment Signal: Buy
Current Market Cap: A$392.6M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.